TuHURA Biosciences (HURA) 10-K 7 Oct 24 2024 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Oct. 07, 2024	Dec. 31, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Trading Symbol	KTRA
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Registrant Name	Kintara Therapeutics, Inc.
Entity Central Index Key	0001498382
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 1,723,383
Entity Common Stock, Shares Outstanding		55,660,578,000
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Incorporation, State or Country Code	NV
Entity File Number	001-37823
Entity Tax Identification Number	99-0360497
Entity Address, Address Line One	9920 Pacific Heights Blvd
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	350-4364
Document Annual Report	true
Document Transition Report	false
Document Financial Statement Error Correction [Flag]	false
Auditor Name	Marcum LLP
Auditor Firm ID	688
Auditor Location	San Francisco, CA
Documents Incorporated by Reference	None.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Current assets
Cash and cash equivalents	$ 4,909	$ 1,535
Prepaid expenses, deposits and other	414	660
Clinical trial deposit	205	1,075
Total current assets	5,528	3,270
Property and equipment, net	674	709
Total assets	6,202	3,979
Current liabilities
Accounts payable and accrued liabilities	2,207	2,784
Related party payables	52	298
Total current liabilities	2,259	3,082
Milestone payment liability	186	166
Total liabilities	2,445	3,248
Stockholders’ equity
Common stock Authorized 75,000 shares at June 30, 2024 (June 30, 2023 - 75,000), $0.001 par value Issued and outstanding 55,305 issued at June 30, 2024 (June 30, 2023 1,692)	55	2
Additional paid-in capital	153,305	141,438
Accumulated deficit	(159,876)	(151,375)
Accumulated other comprehensive income	21	21
Total stockholders’ equity	3,757	731
Total liabilities and stockholders’ equity	6,202	3,979
Preferred Stock Series A
Stockholders’ equity
Preferred stock	279	279
Preferred Stock Series C
Stockholders’ equity
Preferred stock	$ 9,973	$ 10,366

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Jun. 30, 2023
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	55,305,000	1,692,000
Preferred Stock Series A
Preferred Stock, shares issued	279,000	279,000
Preferred stock, shares outstanding	279,000	279,000
Preferred Stock Series C
Preferred Stock, shares issued	14,000	14,000
Preferred stock, shares outstanding	14,000	14,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Expenses
Research and development	$ 2,663	$ 9,311
General and administrative	5,788	5,485
Operating expenses	(8,451)	(14,796)
Other income / (loss)
Foreign exchange	(8)	10
Interest - net	139	137
Other income	131	147
Net loss for the year	(8,320)	(14,649)
Computation of basic loss per share
Net loss for the year	(8,320)	(14,649)
Series A Preferred cash dividend	(8)	(8)
Series C Preferred stock dividend	(173)	(362)
Net loss for the year attributable to common stockholders	$ (8,501)	$ (15,019)
Basic and fully diluted loss per share	$ (0.32)	$ (9.27)
Basic and fully diluted weighted average number of shares	26,352,000	1,620,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Accumulated deficit
Beginning Balance at Jun. 30, 2022	$ 11,795,000	$ 1,000	$ 135,575,000	$ 21,000	$ 12,554,000	$ (136,356,000)
Beginning Balance, shares at Jun. 30, 2022		1,311,000
Issuance of shares and warrants - net of issue costs	$ 1,903,000	$ 1,000	$ 1,902,000
Issuance of shares and warrants - net of issue costs, shares		262,000
Issuance of shares for services	110,000		110,000
Issuance of shares for services, shares		$ 16,000
Conversion of Series C Preferred stock to common stock			$ 1,909,000		(1,909,000)
Conversion of Series C preferred stock to common stock, shares		45,000
Additional shares issued on reverse stock split, shares		15,000
Stock option expense	$ 1,490,000		1,490,000
Restricted stock unit expense	90,000		90,000
Series A preferred cash dividend	(8,000)					(8,000)
Series B preferred stock dividend			362,000			(362,000)
Series B preferred stock dividend, shares		43,000
Net loss for the year	(14,649,000)					(14,649,000)
Ending Balance at Jun. 30, 2023	731,000	$ 2,000	141,438,000	21,000	10,645,000	(151,375,000)
Ending Balance, shares at Jun. 30, 2023		1,692,000
Issuance of shares and warrants - net of issue costs	10,576,000	$ 53,000	10,523,000
Issuance of shares and warrants - net of issue costs, shares		53,551,000
Issuance of shares on vesting of restricted stock units, shares		4,000
Conversion of Series C Preferred stock to common stock	393,000		393,000		(393,000)
Conversion of Series C preferred stock to common stock, shares		9,000
Stock option expense	607,000		607,000
Restricted stock unit expense	171,000		171,000
Series A preferred cash dividend	(8,000)					(8,000)
Series C Preferred Stock Dividend			173,000			(173,000)
Series C Preferred Stock Dividend Shares		49,000
Net loss for the year	(8,320,000)					(8,320,000)
Ending Balance at Jun. 30, 2024	$ 3,757,000	$ 55,000	$ 153,305,000	$ 21,000	$ 10,252,000	$ (159,876,000)
Ending Balance, shares at Jun. 30, 2024		55,305,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss for the year	$ (8,320)	$ (14,649)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation of property and equipment	55	60
Amortization of clinical trial deposit		3,225
Change in fair value of milestone liability	20	3
Restricted stock units and shares issued for services	171	200
Stock option expense	607	1,490
Changes in operating assets and liabilities
Prepaid expenses, deposits and other	246	371
Clinical trial deposits	870	(1,700)
Accounts payable and accrued liabilities	(577)	(442)
Related party payables	(248)	(423)
Net cash used in operating activities	(7,176)	(11,865)
Cash flows from investing activities
Purchase of equipment	(20)	(232)
Net cash used in investing activities	(20)	(232)
Cash flows from financing activities
Net proceeds from the issuance of shares and warrants	10,576	1,903
Payment of prior year issuance costs		(43)
Series A preferred cash dividend	(6)	(8)
Net cash provided by financing activities	10,570	1,852
Increase (decrease) in cash and cash equivalents	3,374	(10,245)
Cash and cash equivalents – beginning of year	1,535	11,780
Cash and cash equivalents – end of year	$ 4,909	$ 1,535

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (8,320)	$ (14,649)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of operations, corporate

Nature of operations, corporate history, and going concern and management plans	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of operations, corporate history, and going concern and management plans	1. Nature of operations, corporate history, and going concern and management plans Nature of operations Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing one late-stage therapeutics - REM-001 for cutaneous metastatic breast cancer (“CMBC”). In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates. Corporate history The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation ("Adgero") in which Adgero continued its existence under Delaware law and became a direct, wholly-owned subsidiary of the Company. Following the completion of the merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC ("Nasdaq") under the symbol “KTRA”. Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero. The Company is also the parent company to Kayak Mergeco, Inc. (“Kayak Mergeco”), a Delaware company, formed to facilitate the proposed merger with TuHURA Biosciences, Inc. as described below. References to the Company refer to the Company and its wholly-owned subsidiaries. Going concern and management plans These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the year ended June 30, 2024, the Company reported a loss of $ 8,320 and a negative cash flow from operations of $ 7,176 . The Company had an accumulated deficit of $ 159,876 and had cash and cash equivalents of $ 4,909 as of June 30, 2024. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. On August 2, 2 022, the Company entered into a stock purchase agreement under which the Company has issued 662 shares of common stock for $ 2,008 in net proceeds as of June 30, 2024. In addition, on June 28, 2023, the Company announced that it had been awarded approximately $ 2,000 in grant funding to be received over a two-year period for its REM-001 project. During the year ended June 30, 2024, the Company issued an additional 53,151 shares of common stock for net proceeds of $ 10,471 from its at-the-market ( “ATM”) facility, issued an additional 400 shares of common stock for net proceeds of $ 105 from its Lincoln Park Purchase Agreement (Note 8), and announced that it is suspending the development of VAL-083. Even with the proceeds from the grant funding, the stock purchase financing, and the ATM sales, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these condensed consolidated interim financial statements. On April 2, 2024, the Company entered into a merger agreement with TuHURA Biosciences, Inc. Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, debt, and/or entering into strategic partnership arrangements. However, the Company’s ability to raise additional capital could be affected by various risks and uncertainties including, but not limited to, global unrest. The Company may not be able to raise sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. These consolidated financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material. Merger with TuHURA Biosciences, Inc. On April 2, 2024, the Company, Kayak Mergeco, a wholly-owned subsidiary of Kintara incorporated in the State of Delaware, a nd TuHURA Biosciences, Inc., a Delaware corporation (“TuHURA”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Kayak Mergeco will merge with and into TuHURA, with TuHURA surviving the merger and becoming a direct, wholly-owned subsidiary of the Company (the “Merger”). Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), (i) each then-outstanding share of TuHURA common stock, par value $ 0.001 per share (the “TuHURA Common Stock”) (other than any shares held in treasury and Dissenting Shares (as defined in the Merger Agreement)) will be converted into shares of the Company’s common stock equal to the Exchange Ratio, as such term is defined in the Merger Agreement, (ii) each then-outstanding TuHURA stock option will be assumed and converted into an option to purchase shares of the Company’s common stock, subject to certain adjustments as set forth in the Merger Agreement, and (iii) each then-outstanding warrant to purchase shares of TuHURA Common Stock (the “TuHURA Warrants”) will be assumed and converted into and exchangeable for a warrant of like tenor entitling the holder to purchase shares of the Company’s common stock, subject to certain adjustments as set forth in the Merger Agreement. In addition to the foregoing, the Merger Agreement provides that, at the closing of the Merger, the corporate name of the Company will be changed to “TuHURA Biosciences, Inc.” Existing Company stockholders will receive contingent value rights (“CVR”), entitling them to receive shares of the Company's common stock upon achievement of enrollment of a minimum of 10 patients in the REM-001 clinical trial, with such patients each completing 8 weeks of follow-up on or before December 31, 2025. Under the terms of the Merger Agreement, on a pro forma basis, post-merger Company stockholders are expected to collectively own approximately 2.85 %, or approximately 5.45 % including the shares underlying the CVR, of the common stock of the post-merger combined company on a pro forma fully diluted basis. TuHURA stockholders are expected to collectively own approximately 97.15 %, or 94.55 % assuming the distribution of the CVR shares, of the common stock of the combined company on a pro forma fully diluted basis. The transaction is anticipated to close in the fourth calendar quarter of 2024 and remains subject to regulatory approval as of October 7, 2024. Termination Fees Payable by Kintara If the Merger Agreement is terminated by either the Company or TuHURA under certain circumstances, the Company must pay TuHURA a termination fee of $ 1,000 . If TuHURA terminates the Merger Agreement under certain circumstances, the Company must reimburse TuHURA for expenses incurred by TuHURA in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $ 750 . Termination Fees Payable by TuHURA If the Merger Agreement is terminated by either the Company or TuHURA under certain circumstances, TuHURA must pay the Company a termination fee of $ 1,000 . If the Company terminates the Merger Agreement under certain circumstances, TuHURA must reimburse the Company for expenses incurred by the Company in connection with the Merger Agreement and the transactions contemplated thereby, up to a maximum of $ 750 .

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Significant accounting policies	2. Significant accounting policies Reverse stock split On November 10, 2022, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, in order to effectuate a 1: 50 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock as well as its authorized shares of common stock. As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein. Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below and have been consistently applied to all periods presented. Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar BC, Callco, Exchangeco, and Kayak Mergeco as of, and for the years ended June 30, 2024, and 2023. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services, the milestone payment liability, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements. Cash and cash equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of three months or less that can be readily convertible into known amounts of cash. Cash and cash equivalents are held at recognized Canadian and United States financial institutions. Interest earned is recognized in the consolidated statement of operations. Foreign currency translation The functional currency of the Company at June 30, 2024, is the United States dollar. Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign-currency denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange losses or gains in the consolidated statement of operations. Non-monetary assets and liabilities are translated at historical exchange rates. Expenses are translated at average exchange rates during the period. Exchange gains and losses are included in consolidated statement of operations for the period. Property and equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over its estimated useful life of three to seven years . Depreciation expense is recognized from the date the equipment is put into use. Income taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. To the extent that deferred tax assets cannot be recognized under the preceding criteria, the Company establishes valuation allowances, as necessary, to reduce deferred tax assets to the amounts expected to be realized. As of June 30, 2024, and 2023, all deferred tax assets were fully offset by a valuation allowance. The realization of deferred tax assets is dependent upon future federal, state and foreign taxable income. The Company’s judgments regarding deferred tax assets may change due to future market conditions, as the Company expands into international jurisdictions, due to changes in U.S. or international tax laws and other factors. These changes, if any, may require material adjustments to the Company’s deferred tax assets, resulting in a reduction in net income or an increase in net loss in the period in which such determinations are made. The Company recognizes the impact of uncertain tax positions based upon a two-step process. To the extent that a tax position does not meet a more-likely-than-not level of certainty, no impact is recognized in the consolidated financial statements. If a tax position meets the more-likely-than-not level of certainty, it is recognized in the consolidated financial statements at the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s policy is to analyze the Company’s tax positions taken with respect to all applicable income tax issues for all open tax years in each respective jurisdiction. Interest and penalties with respect to uncertain tax positions would be included in income tax expense. As of June 30, 2024, the Company concluded that there were no uncertain tax provisions required to be recognized in its consolidated financial statements. The Company does not record U.S. income taxes on the undistributed earnings of its foreign subsidiaries based upon the Company’s intention to permanently reinvest undistributed earnings to ensure sufficient working capital and further expansion of existing operations outside the United States. As June 30, 2024, the Company’s foreign subsidiaries operated at a cumulative deficit for U.S. earnings and profit purposes. In the event the Company is required to repatriate funds from outside of the United States, such repatriation would be subject to local laws, customs, and tax consequences. Determination of the amount of unrecognized deferred tax liability related to these earnings is not practicable. Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and • Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As of June 30, 2024, the Company’s milestone payment liability was measured using level 3 inputs. The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments. Intangible assets Patents Expenditures associated with the filing, or maintenance of patents, licensing or technology agreements are expensed as incurred. Costs previously recognized as an expense are not recognized as an asset in subsequent periods. If the Company achieves regulatory approval, patent costs will be deferred and amortized over the remaining life of the related patent. Accruals for research and development expenses and clinical trials As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended June 30, 2024, and 2023, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials. Warrants and shares issued for services The Company has issued equity instruments for services provided by employees and non-employees. The equity instruments are valued at the fair value of the instrument issued. Stock options The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. Prior to our adoption of Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), stock options granted to non-employee consultants were revalued at the end of each reporting period until vested using the Black-Scholes option-pricing model and the changes in their fair value were recorded as adjustments to expense over the related vesting period. For the years ended June 30, 2024, and 2023, the determination of grant-date fair value for stock option awards was estimated using the Black-Scholes model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. For years ended June 30, 2024, and 2023, the Company utilized the plain vanilla method to determine the expected life of stock options. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. Restricted stock units The Company recognizes compensation costs resulting from the issuance of restricted stock units (“RSUs”) as an expense in the statement of operations over the service period based on a measurement of fair value for each RSU award. The RSUs are valued using the closing price of the Company’s common stock on the date of issuance with the total expense being recognized over the vesting period of the respective RSUs. Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the years ended June 30, 2024, and 2023, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, restricted stock units, and convertible preferred shares is anti-dilutive. As of June 30, 2024, potential common shares of 677 (2023 – 713 ) related to outstanding common share warrants, 42 (2023 – 42 ) related to outstanding Series C preferred stock warrants, 222 (2023 – 198 ) related to stock options, 66 (2023 - 78 ) related to restricted stock units, and 235 (2023 – 245 ) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share. Segment information The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single operating segment being the research and development of cancer indications, and operates primarily in one geographic area, being North America. The Company previously conducted one clinical trial in China but the expenses incurred over the course of the study were not significant. All of the Company’s assets are located in either Canada or the United States. Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280)” (“ASU 2023-07”). The amendments in ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report a measure of segment profit or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in ASU 2023-07 do not change or remove those disclosure requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively. Management considers that the guidance does not have a significant impact on the disclosures set out in these consolidated financial statements. In December 2023, FASB issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740)” (“ASU 2023-09”). The amendments in ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU 2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit) from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an annual basis, the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective for annual periods beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact of the update on the Company’s consolidated financial statements and related disclosures. Except as disclosed elsewhere, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company’s consolidated financial statements.

Clinical Trial Deposit

Clinical Trial Deposit	12 Months Ended
	Jun. 30, 2024
Other Liabilities [Abstract]
Clinical Trial Deposit	3. Clinical trial deposit In October 2020, the Company announced that it had entered into a final agreement with a contract research organization (“CRO”) for the management of the Company’s registrational study of VAL-083 for glioblastoma. Under the agreement, the Company supplied the drug for the study and the CRO managed all operational aspects of the study including site activation and patient enrollment. The Company was required to make certain payments under the agreement related to patient enrollment milestones. For the year ended June 30, 2024, the Company has recognized an expense of $ 563 (2023 - $ 5,065 ), respectively, for this study in relation to clinical site initiation and patient enrollment. On October 31, 2023, the Company announced that preliminary topline results from this registrational study for VAL-083 did not perform better than the current standards of care in glioblastoma. As a result, the Company announced that it has terminated the development of VAL-083. In the year ended June 30, 2024, the remaining deposit of $ 1,075 was offset against amounts owing to the CRO and the agreement with the CRO was terminated with an additional final cost of $ 1,000 , which was paid in the year ended June 30, 2024. In the year ended June 30, 2024, the Company recorded $ 205 as a deposit with a CRO for the management of the Company’s 15-patient study of REM-001 for cutaneous metastatic breast cancer (“CMBC”).

Clinical Trials Grant

Clinical Trials Grant	12 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Clinical Trials Grant	4. Clinical trials grant Effective July 1, 2023, the Company was awarded a $ 2,000 Small Business Innovation Research grant from the National Institutes of Health ("NIH") to support the clinical development of REM-001 for the treatment of cutaneous metastatic breast cancer. The grant will be received in two tranches: approximately $ 1,250 for the period July 1, 2023, to June 30, 2024, and approximately $ 750 for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patient clinical trial was re-started. The grant is expended to the Company as a reimbursement of expenditures incurred. During the year ended June 30, 2024, the Company received $ 827 (2023 - nil ) for grants received against research and development expenditures in the period. The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Property and equipment, net	5. Property and equipment, net $ Balance, June 30, 2022 90 Additions 679 Less depreciation ( 60 ) Balance, June 30, 2023 709 Additions 20 Less depreciation ( 55 ) Balance, June 30, 2024 674 At June 30, 2024, the total capitalized cost of property and equipment was $ 879 (June 30, 2023 - $ 859 ), of which $ 499 is not in use. The Company has recognized $ 55 (2023 - $ 60 ) in depreciation expense for the year ended June 30, 2024, on equipment in use.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related party transactions	6. Related party transactions Valent Technologies, LLC Agreements On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083 owned by Valent. The Company now owns all rights and title to VAL-083 and is responsible for further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $ 279 (including aggregate accrued interest to September 30, 2014, of $ 29 ), issued to Valent by Del Mar (BC), for 279 shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $ 1.00 per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3 % of the Series A Stated Value per year, payable quarterly in arrears. For the year ended June 30, 2024, the Company recorded $ 8 (2023 - $ 8 ) related to the dividends paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit. On February 13, 2024, the Company sent an Opt-Out Notice to Valent under the Valent Assignment Agreement whereby the Company assigned all rights, title and interest in and to the patents for VAL-083 to Valent. As a result, the Company granted Valent a non-exclusive, fully-paid, royalty-free, perpetual, worldwide and non-transferable license, subject to limited exceptions. The Company is entitled to receive royalties from Valent’s subsequent commercialization of VAL-083 equal to 5 % of Valent Net Sales (as defined in the Valent Assignment Agreement). Related party payables At June 30, 2024 there is an aggregate amount of $ 52 (2023 - $ 298 ) payable to the Company’s officers and directors for fees, expenses, and accrued bonuses and other liabilities.

Milestone Payment Liability

Milestone Payment Liability	12 Months Ended
	Jun. 30, 2024
Business Combinations [Abstract]
Milestone Payment Liability	7. Milestone payment liability The milestone payment liability relates to an asset purchase agreement with St. Cloud Investments, LLC (“St. Cloud”) that the Company has relating to the acquisition of REM-001. The agreement, as amended, is dated November 26, 2012 (the “St. Cloud Agreement”). Pursuant to the terms of the St. Cloud Agreement, the Company is obligated to make certain payments under the agreement. The future contingent amounts payable under that agreement are as follows: • Upon the earlier of (i) a subsequent equity financing to take place after the Company conducts a Phase 2B clinical study in which fifty patients complete the study and their clinical data can be evaluated or (ii) the commencement of a clinical study intended to be used as a definitive study for market approval in any country, the Company is obligated to pay an aggregate amount of $ 300 in cash or an equivalent amount of common stock, with $ 240 to St. Cloud and $ 60 to an employee of the Company; and • Upon receipt of regulatory approval of REM-001 Therapy, the Company is obligated to pay an aggregate amount of $ 700 in cash or an equivalent amount of common stock, with $ 560 to St. Cloud and $ 140 to an employee of the Company. With respect to the $300 and $700 potential milestone payments referenced above (each a “Milestone Payment”), if either such Milestone Payment becomes payable, and in the event the Company elects to pay either such Milestone Payment in shares of its common stock, the value of the common stock will equal the average of the closing price per share of the Company’s common stock over the twenty (20) trading days following the first public announcement of the applicable event described above. The milestone payment liability has been estimated using a scenario-based method (or “SBM”). An SBM is an income-based approach under which possible outcomes are identified, the contingent consideration payoff of each outcome is probability weighted, and then a suitable discount rate is used to arrive at the expected present value of the contingent consideration at the valuation date. The probability used in the valuation was based on published research for the probability of success of oncology companies at a similar stage of development as the Company. The discount rate was based on published rates for corporate bonds and the term was based on an estimate of the planned timing of completion of the respective development achievement that would result in payment of the respective milestones. $ Balance – June 30, 2022 163 Change in fair value estimate 3 Balance – June 30, 2023 166 Change in fair value estimate 20 Balance – June 30, 2024 186

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ equity Preferred stock Series C Preferred Stock Series C Preferred Stock Number $ Balance – June 30, 2022 16,838 12,275 Conversion of Series C Preferred stock to common stock ( 2,630 ) ( 1,909 ) Balance – June 30, 2023 14,208 10,366 Conversion of Series C Preferred stock to common stock ( 540 ) ( 393 ) Balance – June 30, 2024 13,668 9,973 In August 2020, the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2, and C-3). Each share of Series C Preferred Stock was issued at a purchase price of $ 1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were determined at the closing of each round of the private placement. The conversion prices for the Series C-1 Preferred Stock, Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are $ 58.00 , $ 60.70 , and $ 57.50 , respectively. Subject to ownership limitations, the owners of the Series C-1 Preferred Stock, the Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are entitled to receive dividends, payable in shares of common stock at a rate of 10 %, 15 %, 20 % and 25 %, respectively, of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock, on the 12 th , 24 th , 36 th and 48 th month, anniversary of the initial closing of the private placement. The Company paid the 12 th , 24 th , 36 th , and 48 th month anniversary dividends of 10 %, 15 %, 20 %, and 25 % common stock dividends on August 19, 2021, 2022, 2023, and 2024, respectively. The Series C Preferred Stock dividends do not require declaration by the board of directors and are accrued annually as of the date the dividend is earned in an amount equal to the fair value of the Company’s common stock on the dates the respective dividends are paid. The fair value of the Series C Preferred Stock dividend paid on August 19, 2023, was determined by multiplying the dividends paid of 49 shares of common stock by the Company’s closing share price on August 19, 2023, of $ 3.53 per share for a total fair value of $ 173 . Any outstanding shares of Series C Preferred Stock were automatically converted to shares of common stock on August 19, 2024 (Note 13). In addition, as part of the Series C Preferred financing, the Company issued warrants to the placement agent (“Series C Agent Warrants”), which expired on August 19, 2024. The Series C Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series C Preferred Stock. The Series C Preferred Stock is pari passu in liquidation to the Company’s Series A Preferred Stock. The liquidation value of the Series C Preferred Stock at June 30, 2024, is the stated value of $ 9,973 (June 30, 2023 - $ 10,366 ). The Company’s Series C Preferred Stock outstanding, conversion shares, and future dividends as of June 30, 2024, are as follows: Series Number Conversion Price Number of conversion shares Dividend Shares Series 1 10,925 58.00 188 151 Series 2 898 60.70 15 10 Series 3 1,845 57.50 32 24 13,668 235 185 Series C Dividends Dividend Shares 10% - August 19, 2021 (actual) 34 15% - August 19, 2022 (actual) 43 20% - August 19, 2023 (actual) 49 25% - August 19, 2024 (actual) 59 185 Series A Preferred Stock Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 279 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $ 1.00 per share (the “Series A Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3 % of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. The Series A Preferred Stock is held by Valent (note 5). The Series A Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock, and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock is pari passu in liquidation to the Company’s Series C Preferred Stock. The liquidation value of the Series A Preferred stock at June 30, 2024, is its stated value of $ 279 (June 30, 2023 - $ 279 ). There was no change to the Series A Preferred stock for the years ended June 30, 2024, or 2023. Common stock Amended articles of incorporation On June 30, 2023, the Company amended its articles of incorporation to increase the number of authorized shares of common stock from 5,500 to 75,000 shares. Stock issuances Year ended June 30, 2024 On September 19, 2023, the Company entered into a Sales Agreement, (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of common stock having an aggregate offering price of up to $ 2,850 (the “ATM Facility”), subsequently increased to $ 10,900 on December 18, 2023. From October 31, 2023, until June 30, 2024, the Company raised $ 10,471 in net proceeds, after deducting share issuance costs of $ 435 , from the sale of 53,151 shares of its common stock at a weighted average price of $ 0.21 per share under the ATM Facility. On February 22, 2024, the Company determined that it had concluded utilization of the ATM Facility. Sales of the shares of common stock made under the ATM Facility may be made in negotiated transactions, or by any method permitted by law that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on The Nasdaq Capital Market or sales made to or through a market maker other than on an exchange. Pursuant to the Sales Agreement, the Company has the right, in its sole discretion, to present the Agent with a placement notice directing the Agent to purchase a number of shares of common stock under the ATM Facility, subject to the terms and conditions of the Sales Agreement. The purchase price per share under the ATM Facility will be based on market prices of the common stock on the applicable purchase date for such purchases. The Agent is entitled to a commission rate of 3.0 % of the gross sales price per share sold under the Sales Agreement. During the year ended June 30, 2024, the Company sold 400 shares of common stock at a weighted average price of $ 0.23 per share for total net proceeds of approximately $ 105 under the Purchase Agreement with Lincoln Park (as defined below). During the year ended June 30, 2024, the Company issued 4 shares of common stock on vesting of restricted stock units during the period. On February 22, 2024, the Company determined that it had concluded utilization of the equity facility pursuant to the terms of the Purchase Agreement with Lincoln Park. Year ended June 30, 2023 On August 2, 2022, the Company entered into a stock purchase agreement, dated as of August 2, 2022, (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase up to a maximum of $ 20,000 of shares of the Company’s common stock (the “Purchase Shares”). Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed to take certain actions relating to the registration of the offer and sale of the Purchase Shares available for issuance under the Purchase Agreement. Upon execution of the Purchase Agreement, the Company issued 33 shares of common stock to Lincoln Park as a commitment fee in connection with entering into the Purchase Agreement. Pursuant to the Purchase Agreement, the Company has the right, in its sole discretion, to present Lincoln Park with a purchase notice directing Lincoln Park to purchase up to 10 Purchase Shares provided that the closing sale price of the common stock on the purchase date is not below a threshold price set forth in the Purchase Agreement (a “Regular Purchase”). The Company and Lincoln Park may mutually agree to increase the Regular Purchase amount with respect to any Regular Purchase under the Purchase Agreement, provided that Lincoln Park’s maximum committed purchase obligation under any single Regular Purchase shall not exceed $ 2,000 . The purchase price per share for each Regular Purchase is based on prevailing market prices of the common stock immediately preceding the time of sale as computed in accordance with the terms set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for the Purchase Shares under the Purchase Agreement. If the Company directs Lincoln Park to purchase the maximum number of shares of common stock that the Company may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park to purchase additional shares of common stock in an “accelerated purchase” (each, an “Accelerated Purchase”) and an “additional accelerated purchase” (each, an “Additional Accelerated Purchase”) (including multiple Additional Accelerated Purchases on the same trading day) as provided in the Purchase Agreement. The purchase price per share for each Accelerated Purchase and Additional Accelerated Purchase will be based on market prices of the common stock on the applicable purchase date for such Accelerated Purchases and such Additional Accelerated Purchases. The aggregate number of shares that the Company can issue or sell to Lincoln Park under the Purchase Agreement may in no case exceed 262 shares of the common stock (which is equal to approximately 19.99 % of the shares of the common stock outstanding immediately prior to the execution of the Purchase Agreement) (the “Exchange Cap”), unless (i) stockholder approval is obtained to issue Purchase Shares above the Exchange Cap, in which case the Exchange Cap will no longer apply, or (ii) the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $ 10.12 per share (which represents the lower of (A) the official closing price of the Company’s common stock on Nasdaq on the trading day immediately preceding the date of the Purchase Agreement and (B) the average official closing price of the Company’s common stock on Nasdaq for the five consecutive trading days ending on the trading day on the date of the Purchase Agreement, adjusted such that the transactions contemplated by the Purchase Agreement are exempt from the Exchange Cap limitation under applicable Nasdaq rules). The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. During the year ended June 30, 2023, the Company sold 229 shares of common stock for total net proceeds of approximately $ 1,903 under the Purchase Agreement. As of June 30, 2024, the sales made under the Purchase Agreement are the maximum amounts available due to ownership limitations under Nasdaq rules. Shares issued for services During the year ended June 30, 2023, the Company issued 16 shares of common stock for services for a total value of $ 110 . 2017 Omnibus Incentive Plan As subsequently approved by the Company’s stockholders at an annual meeting of stockholders, on April 11, 2018, the Company’s board of directors approved the adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”), as amended. The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) as well as a Restricted Stock Unit ("RSU") award under the 2017 Plan. As approved by the Company’s stockholders on June 21, 2022, the number of common shares available under the 2017 Plan as of June 30, 2024, is 440 shares, less the number of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”), or that are subject to grants of stock options made, or that may be made, under the Legacy Plan, or that have been previously exercised. The following table sets forth the aggregate information on all equity compensation plans as of June 30, 2024: Plan Category (in thousands, except per share amounts) Number of shares of common stock to be issued upon exercise of outstanding stock options and rights Weighted-average exercise price of stock options and rights Number of shares of common stock remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by security holders - 2017 Plan (1) 288 $ 21.40 144 Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan — $ 2,060.08 — Totals 288 $ 30.70 144 (1) The Del Mar (BC) 2013 Amended and Restated Stock Option Plan refers to the Company’s previous equity compensation plan. (2) The balance of 144 shares of common stock available for issuance under the 2017 Plan as of June 30, 2024, is net of stock options previously exercised. The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8 % of the Company’s fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on, or after, July 7, 2027. Stock options During the year ended June 30, 2024, a total of 89 stock options to purchase shares of common stock were granted to directors and officers of the Company. The 89 options granted have an exercise price of $ 4.655 per share and vest as to 25 % on August 30, 2024, with the remaining portion vesting in equal monthly installments over a period of 36 months from September 30, 2024 to September 30, 2027. All of the options to purchase shares of common stock granted have a 10 -year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions. The following table sets forth changes in stock options outstanding under all plans: Number of Weighted Balance – June 30, 2022 176 87.05 Granted 78 8.79 Expired ( 56 ) 102.65 Balance – June 30, 2023 198 51.71 Granted 89 4.66 Expired ( 34 ) 107.69 Forfeited ( 31 ) 8.26 Balance – June 30, 2024 222 30.70 The following table summarizes stock options outstanding and exercisable under all plans at June 30, 2024: Exercise price Number Weighted Number 4.655 79 9.17 21 6.04 9 8.64 3 8.79 34 8.09 17 12.75 to 16.25 6 8.27 6 30.50 to 48.00 73 7.31 48 62.00 to 68.50 13 6.81 13 85 7 6.21 7 304.95 to 2,660.00 1 1.93 1 222 116 Stock options issued during the years ended June 30, 2024, and 2023, have been valued using a Black-Scholes pricing model with the following assumptions: June 30, June 30, Dividend rate — % — % Volatility 91.4 % 91.4 % Risk-free rate 4.24 % 2.67 % Term – years 6.1 6.1 The estimated volatility of the Company’s common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the stock options at the valuation date. The expected life of the stock options has been estimated using the plain vanilla method. The Company has recognized the following amounts as stock option expense for the periods noted: Years ended June 30, 2024 2023 Research and development 187 451 General and administrative 420 1,039 607 1,490 All of the stock option expense for the periods ended June 30, 2024, and 2023, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding at June 30, 2024, was nil (2023 - nil ) and the aggregate intrinsic value of stock options exercisable at June 30, 2024, was nil (2023 - nil ). As of June 30, 2024, there was $ 322 in unrecognized compensation expense that will be recognized over the next 2.02 years. The following table sets forth changes in unvested stock options under all plans: Number of Weighted Unvested at June 30, 2022 84 51.23 Granted 78 8.79 Vested ( 44 ) 48.53 Unvested at June 30, 2023 118 24.12 Granted 89 4.66 Vested ( 70 ) 19.44 Forfeited ( 31 ) 8.26 Unvested at June 30, 2024 106 15.57 The aggregate intrinsic value of unvested stock options at June 30, 2024 was nil (2023 - nil ). The unvested stock options have a remaining weighted average contractual term of 7.72 (2023 – 8.83 ) years. Restricted stock units On August 1, 2022, the Company issued 18 RSUs to its officers. Subject to providing continuous service to the Company, the RSUs vest in four equal annual installments commencing August 1, 2023 . The RSUs were valued using the closing price of the Company’s common stock on the date of issuance with the total expense of $ 155 being recognized over the vesting period of four years . On June 1, 2023, the Company issued 60 RSU to one of its officers. Subject to providing continuous service to the Company, the RSUs all fully vest on June 1, 2024. The RSUs were valued using the closing price of the Company’s common stock on the date of issuance with the total expense of $ 186 being recognized over the vesting period of one year . As of June 30, 2024, 4 RSU had vested and were converted to common shares, and 60 RSU had vested but were converted to common shares subsequent to June 30, 2024. During the year ended June 30, 2024, the Company recognized a total of $ 171 (2023 - $ 90 ) related to RSU. Number of Balance – June 30, 2022 — Issuance 78 Balance – June 30, 2023 78 Vested and converted to common shares ( 4 ) Forfeited ( 8 ) Balance – June 30, 2024 66 Common stock warrants The following table sets forth changes in outstanding warrants: Number of Weighted average exercise price Balance – June 30, 2022 720 49.36 Expiry of 2018 Investor and Agent warrants ( 7 ) 625.68 Balance – June 30, 2023 713 43.55 Expiry of warrants issued for services ( 20 ) 71.53 Expiry of 2019 Investor and Agent warrants ( 16 ) 157.25 Balance – June 30, 2024 677 39.99 The following table summarizes the Company’s outstanding warrants as of June 30, 2024: Description of warrants Number Exercise Expiry date 2022 April Investor warrants 325 20.50 April 14, 2027 2022 Investor warrants 240 62.50 March 28, 2025 2020 Investor warrants 65 50.00 August 16, 2024 NBTS Warrants 3 54.50 June 19, 2025 2022 April Agent warrants 32 33.12 October 14, 2026 2022 Agent warrants 12 78.12 March 28, 2025 677 Series C preferred stock warrants In connection with the Series C Preferred Stock private placement, the Company issued 2,504 Series C Agent Warrants. The Series C Agent Warrants have an exercise price of $ 1,000 per share, provide for a cashless exercise feature, and are exercisable for a period of four years from August 19, 2020. The Series C Preferred Stock issuable upon exercise of the Series C Agent Warrants is convertible into shares of common stock in the same manner as each respective underlying series of outstanding Series C Preferred Stock and will be entitled to the same dividend rights as each respective series. The following table sets forth changes in outstanding Series C Agent Warrants: Balance, Number of Number of Balance, Exercise Issuance of Preferred Series C-1 Agent Warrants 1,929 — — 1,929 58.00 Issuance of Preferred Series C-2 Agent Warrants 219 — — 219 60.70 Issuance of Preferred Series C-3 Agent Warrants 296 — — 296 57.50 2,444 — — 2,444 The following table summarizes the Company’s outstanding Series C Agent Warrants as of June 30, 2024: Series C Agent Warrants Number Conversion Number of Cumulative Series 1 1,929 58.00 33 23 Series 2 219 60.70 4 3 Series 3 296 57.50 5 4 2,444 42 30 The Series C Agent Warrants expired unexercised subsequent to June 30, 2024, on August 19, 2024.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	9. Income taxes For the years ended June 30, 2024, and 2023, the Company did not record a provision for deferred income taxes due to a full valuation allowance against the deferred tax assets. Significant components of the Company’s deferred tax assets and deferred tax liabilities are shown below: June 30, June 30, Deferred tax assets: Non-capital losses carried forward 27,911 29,204 Stock-based compensation 1,149 982 Capital losses carried forward — 18 Financing costs — 326 Bonus - compensation 375 37 Scientific research and development 806 895 Scientific research and development – Investment 685 769 Capitalized research and development expenses 604 265 31,530 32,496 Deferred tax liabilities: Scientific research and development – ITC ( 114 ) ( 127 ) Fixed Assets ( 71 ) — 31,345 32,369 Valuation allowance ( 31,345 ) ( 32,369 ) Net future tax assets — — The income tax benefit of these tax attributes has not been recorded in these consolidated financial statements because of the uncertainty of their recovery. The Company’s effective income tax rate differs from the statutory income tax rate of 21 % (2023 – 21 %). The differences arise from the following items: June 30, June 30, Tax recovery at statutory income tax rates ( 1,747 ) ( 3,076 ) Permanent differences 389 ( 1,095 ) Rate change ( 17 ) — Effect of rate differentials between jurisdictions ( 110 ) ( 127 ) Effect of foreign exchange rates 441 66 Scientific research and development – ITC — ( 61 ) Adjustment to prior year's provision versus statutory tax returns 2,075 ( 106 ) Other ( 7 ) 13 Change in valuation allowance ( 1,024 ) 4,386 Current income tax expense — — The Company does no t have any current income tax expense for the year ended June 30, 2024, as there was a taxable loss for this period. The components of the Company’s loss before income taxes for the year ended June 30, 2024, were allocated as follows: $ 6,500 in the U.S. and $ 1,800 in Canada. As of June 30, 2024, the Company had combined U.S. and Canadian net operating loss (“NOL”) carryforwards of $ 109,300 (2023 – $ 109,300 ). The U.S. federal NOL carryforwards consist of $ 15,800 generated before July 1, 2018, which begin expiring on June 30, 2028 , and $ 33,600 that can be carried forward indefinitely, but are subject to the annual 80 % taxable income limitation. The Canadian NOL carryforwards of $ 59,900 begin expiring in 2030 . In addition, the Company has non-refundable Canadian federal investment tax credits of $ 421 (2023 -$ 470 ) that expire between 2031 and 2042 and non-refundable British Columbia investment tax credits of $ 264 (2023 – $ 299 ) that expire between 2024 and 2032 . The Company also has Canadian scientific research and development tax incentives of $ 3,100 (2023 – $ 3,300 ) that do not expire. The Company files U.S. federal, state, and Canadian income tax returns with varying statutes of limitations. For U.S. federal income tax purposes, the tax years ending June 30, 2021, to June 30, 2023, remain open to federal examination and the state income tax years ending June 30, 2020 to June 30, 2023 remain open to state examination. Under Internal Revenue Code (“IRC”) section 7602(a), the IRS may redetermine NOLs generated in closed tax years if these NOLs are applied to an open tax year. For Canadian income tax purposes, the calendar tax years from 2020 to 2023 remain open to examination. The Company currently is not under examination by any tax authority. IRC sections 382 and 383 place a limitation on the amount of taxable income that can be offset by NOL and credit carryforwards after a change in control (generally greater than 50 % change in ownership within a three-year period) of a loss corporation. Generally, after a change in control, a loss corporation cannot deduct NOL and credit carryforwards in excess of the IRC section 382 and 383 limitations. The limitation in the federal and state NOL and research and development credit carryforwards do not impact the deferred tax assets but note that the deferred tax assets are offset by a full valuation allowance. The limitation can result in the expiration of the NOLs and research and development credit carryforwards available. The Company has performed an IRC section 382 and 383 analysis and determined there was an ownership change in 2013. The Company has not performed any IRC section 382 and 383 analyses since 2013. An assessed change in ownership subsequent to 2013 could limit future use of NOL and research and development credit carryforwards. The acquisition of Adgero Biopharmaceuticals Holdings, Inc. also triggers IRC section 382 on the pre-acquisition NOLs. An analysis for IRC section 382 has not been performed at this time on the pre-acquisition NOLs.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	10. Commitments and contingencies The Company has the following obligations over the next five fiscal years ending June 30, 2028: Clinical development The remaining commitments relating to contracts for drug manufacturing, clinical study management and safety for contracts the Company has entered into for its clinical trials as of June 30, 2024, is $ 1,852 . Pursuant to the commitments for clinical trials, the Company has paid a total of $ 205 in deposits related to study initiation and certain study costs (note 3). These deposits are available to be applied against invoices received from the contract research organization but have not been netted against the Company’s commitments for the fiscal year ended June 30, 2024. Office lease The Company currently rents its shared head office on a one-year renewable lease at $ 2.4 per year and until January 2024, rented its administrative offices on a month-to-month basis at a total rate of $ 1.90 (CA $ 2.5 per month) per month. During the year ended June 30, 2024, the Company recorded a total of $ 14 as rent expense (2023 - $ 39 ).

Supplementary Statement of Cash

Supplementary Statement of Cash Flows Information	12 Months Ended
	Jun. 30, 2024
Supplemental Cash Flow Elements [Abstract]
Supplementary statement of cash flows information	11. Supplementary statement of cash flows information Year ended Year ended Series C Preferred Stock common stock dividend (note 8) 173 362 Series A Preferred Stock cash dividend in accounts payable 2 — Non-cash issue costs (note 8) — 289 Equipment additions reclassified from prepaid expenses — 447 Conversion of Series C Preferred Stock to common stock (note 8) 393 — Income taxes paid — — Interest paid — —

Financial Risk Management

Financial Risk Management	12 Months Ended
	Jun. 30, 2024
Risks and Uncertainties [Abstract]
Financial Risk Management	12. Financial risk management Market risk Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company’s income or valuation of its financial instruments. The Company is exposed to financial risk related to fluctuation of foreign exchange rates. Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the United Sates dollar, primarily general and administrative expenses incurred in Canadian dollars. The Company believes that the results of operations, financial position and cash flows would be affected by a sudden change in foreign exchange rates but would not impair or enhance its ability to pay its Canadian dollar accounts payable. The Company manages foreign exchange risk by converting its US$ to CA$ as needed. The Company maintains the majority of its cash in US$. As of June 30, 2024, net Canadian dollar denominated accounts payable and accrued liabilities exposure in US$ totaled $ 36 . a) Foreign exchange risk Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. If foreign exchange rates were to fluctuate within +/-10% of the closing rate at year-end, the maximum exposure is $ 4 . Balances in foreign currencies at June 30, 2024, and 2023, were as follows: June 30, June 30, Trade payables 63 51 Cash 5 13 Interest, taxes, and other receivables 9 8 b) Interest rate risk The Company is subject to interest rate risk on its cash and cash equivalents and believes that the results of operations, financial position and cash flows would not be significantly affected by a sudden change in market interest rates relative to the investment interest rates due to the short-term nature of the investments. As of June 30, 2024, cash and cash equivalents held by the Company were $ 4,909 . The Company’s cash balance currently earns interest at standard bank rates. If interest rates were to fluctuate within +/-10% of the closing rate at year end the impact of the Company’s interest-bearing accounts will not be significant due to the current low market interest rates. The only financial instruments that expose the Company to interest rate risk are its cash and cash equivalents. Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet cash flow requirements associated with financial instruments. The Company continues to manage its liquidity risk based on the outflows experienced for the period ended June 30, 2024, and is undertaking efforts to conserve cash resources wherever possible. The maximum exposure of the Company’s liquidity risk is $ 2,283 as of June 30, 2024. Credit risk Credit risk arises from cash and cash equivalents, deposits with banks, financial institutions, and contractors as well as outstanding receivables. The Company limits its exposure to credit risk, with respect to cash and cash equivalents, by placing them with high quality credit financial institutions. The Company’s cash equivalents consist primarily of operating funds with commercial banks. Of the amounts on deposit with financial institutions, the following table summarizes the amounts at risk should the financial institutions with which the deposits are held cease trading: The maximum exposure of the Company’s credit risk is $ 65 at June 30, 2024, relating to interest, taxes, and other receivables. The credit risk related to uninsured cash and cash equivalents balances is $ 4,382 at June 30, 2024. Cash and Insured Non- 4,909 527 4,382 Concentration of credit risk Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places its cash and cash equivalents in accredited financial institutions and therefore the Company’s management believes these funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent events	13. Subsequent events The Company has evaluated its subsequent events from June 30, 2024, through the date these consolidated financial statements were issued and has determined that there are no subsequent events requiring disclosure in these consolidated financial statements other than the items noted below. Series C Preferred Stock On August 19, 2024, the Company recorded the common stock dividend on its Series C Preferred Stock as well as the Series C Agent Warrants. The common stock dividend corresponds to the 25 % dividend payable on the fourth anniversary of the initial closing of the Series C Preferred Stock which occurred on August 19, 2020. The 25 % stock dividend was payable on August 19, 2024, to the holders of the Series C Preferred Stock on that date. The 25 % dividend is not payable on Series C Preferred Stock or Series C Agent Warrants that were converted, or exercised, prior to August 19, 2024. The dividend resulted in 59 shares of common stock being issued to the Series C Preferred Stockholders. In addition, on August 19, 2024, the Company issued 235 shares of common stock to the holders of the Series C Preferred Stock upon the automatic conversion of the outstanding Series C Preferred Stock. On August 19, 2024, the Series C Agent Warrants expired unexercised. Amendment to Hoffman Employment Agreement Robert E. Hoffman, Chief Executive Officer and Interim Chief Financial Officer of the Company, and the Company are parties to a certain Executive Employment Agreement dated November 8, 2021 (the “Hoffman Employment Agreement”). On October 4, 2024, the Company and Mr. Hoffman entered into an amendment to the Hoffman Employment Agreement (the “Amendment to the Hoffman Employment Agreement”). Pursuant to the Amendment to the Hoffman Employment Agreement, all outstanding stock options previously granted to Mr. Hoffman by the Company vested in full on October 4, 2024 in exchange for Mr. Hoffman agreeing to extend the non-competition restrictions of the Hoffman Employment Agreement for a period of twelve months following the date that his employment terminates with the Company. Proposed Merger On October 4, 2024, at the Company’s Special Meeting of Stockholders, the Company’s stockholders approved the requisite proposals to effect the completion of the proposed Merger with TuHURA. The proposed Merger is expected to be consummated in mid-October 2024, subject to regulatory approval and the satisfaction of the remaining closing conditions under the Merger Agreement.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Reverse Stock Split	Reverse stock split On November 10, 2022, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, in order to effectuate a 1: 50 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock as well as its authorized shares of common stock. As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein.
Basis of Presentation	Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below and have been consistently applied to all periods presented.
Consolidation	Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar BC, Callco, Exchangeco, and Kayak Mergeco as of, and for the years ended June 30, 2024, and 2023. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services, the milestone payment liability, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.
Cash and Cash Equivalents	Cash and cash equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of three months or less that can be readily convertible into known amounts of cash. Cash and cash equivalents are held at recognized Canadian and United States financial institutions. Interest earned is recognized in the consolidated statement of operations.
Foreign Currency Translation	Foreign currency translation The functional currency of the Company at June 30, 2024, is the United States dollar. Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign-currency denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange losses or gains in the consolidated statement of operations. Non-monetary assets and liabilities are translated at historical exchange rates. Expenses are translated at average exchange rates during the period. Exchange gains and losses are included in consolidated statement of operations for the period.
Property and equipment	Property and equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over its estimated useful life of three to seven years . Depreciation expense is recognized from the date the equipment is put into use.
Income Taxes	Income taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. To the extent that deferred tax assets cannot be recognized under the preceding criteria, the Company establishes valuation allowances, as necessary, to reduce deferred tax assets to the amounts expected to be realized. As of June 30, 2024, and 2023, all deferred tax assets were fully offset by a valuation allowance. The realization of deferred tax assets is dependent upon future federal, state and foreign taxable income. The Company’s judgments regarding deferred tax assets may change due to future market conditions, as the Company expands into international jurisdictions, due to changes in U.S. or international tax laws and other factors. These changes, if any, may require material adjustments to the Company’s deferred tax assets, resulting in a reduction in net income or an increase in net loss in the period in which such determinations are made. The Company recognizes the impact of uncertain tax positions based upon a two-step process. To the extent that a tax position does not meet a more-likely-than-not level of certainty, no impact is recognized in the consolidated financial statements. If a tax position meets the more-likely-than-not level of certainty, it is recognized in the consolidated financial statements at the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s policy is to analyze the Company’s tax positions taken with respect to all applicable income tax issues for all open tax years in each respective jurisdiction. Interest and penalties with respect to uncertain tax positions would be included in income tax expense. As of June 30, 2024, the Company concluded that there were no uncertain tax provisions required to be recognized in its consolidated financial statements. The Company does not record U.S. income taxes on the undistributed earnings of its foreign subsidiaries based upon the Company’s intention to permanently reinvest undistributed earnings to ensure sufficient working capital and further expansion of existing operations outside the United States. As June 30, 2024, the Company’s foreign subsidiaries operated at a cumulative deficit for U.S. earnings and profit purposes. In the event the Company is required to repatriate funds from outside of the United States, such repatriation would be subject to local laws, customs, and tax consequences. Determination of the amount of unrecognized deferred tax liability related to these earnings is not practicable.
Financial Instruments	Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and • Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As of June 30, 2024, the Company’s milestone payment liability was measured using level 3 inputs. The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.
Intangible Assets	Intangible assets Patents Expenditures associated with the filing, or maintenance of patents, licensing or technology agreements are expensed as incurred. Costs previously recognized as an expense are not recognized as an asset in subsequent periods. If the Company achieves regulatory approval, patent costs will be deferred and amortized over the remaining life of the related patent.
Accruals for Research and Development Expenses and Clinical Trials	Accruals for research and development expenses and clinical trials As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended June 30, 2024, and 2023, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.
Warrants and Shares Issued For Services	Warrants and shares issued for services The Company has issued equity instruments for services provided by employees and non-employees. The equity instruments are valued at the fair value of the instrument issued.
Stock Options	Stock options The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. Prior to our adoption of Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), stock options granted to non-employee consultants were revalued at the end of each reporting period until vested using the Black-Scholes option-pricing model and the changes in their fair value were recorded as adjustments to expense over the related vesting period. For the years ended June 30, 2024, and 2023, the determination of grant-date fair value for stock option awards was estimated using the Black-Scholes model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. For years ended June 30, 2024, and 2023, the Company utilized the plain vanilla method to determine the expected life of stock options. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Restricted Stock Units	Restricted stock units The Company recognizes compensation costs resulting from the issuance of restricted stock units (“RSUs”) as an expense in the statement of operations over the service period based on a measurement of fair value for each RSU award. The RSUs are valued using the closing price of the Company’s common stock on the date of issuance with the total expense being recognized over the vesting period of the respective RSUs.
Loss Per Share	Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the years ended June 30, 2024, and 2023, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, restricted stock units, and convertible preferred shares is anti-dilutive. As of June 30, 2024, potential common shares of 677 (2023 – 713 ) related to outstanding common share warrants, 42 (2023 – 42 ) related to outstanding Series C preferred stock warrants, 222 (2023 – 198 ) related to stock options, 66 (2023 - 78 ) related to restricted stock units, and 235 (2023 – 245 ) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share.
Segment Information	Segment information The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single operating segment being the research and development of cancer indications, and operates primarily in one geographic area, being North America. The Company previously conducted one clinical trial in China but the expenses incurred over the course of the study were not significant. All of the Company’s assets are located in either Canada or the United States.
Recent Accounting Pronouncements	Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280)” (“ASU 2023-07”). The amendments in ASU 2023-07 improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision useful financial analyses. Topic 280 requires a public entity to report a measure of segment profit or loss that the chief operating decision maker (CODM) uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in ASU 2023-07 do not change or remove those disclosure requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The amendments in ASU 2023-07 are effective for years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, adopted retrospectively. Management considers that the guidance does not have a significant impact on the disclosures set out in these consolidated financial statements. In December 2023, FASB issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740)” (“ASU 2023-09”). The amendments in ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. One of the amendments in ASU 2023-09 includes disclosure of, on an annual basis, a tabular rate reconciliation of (i) the reported income tax expense (or benefit) from continuing operations, to (ii) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09 also requires disclosure of, on an annual basis, the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09 are effective for annual periods beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact of the update on the Company’s consolidated financial statements and related disclosures. Except as disclosed elsewhere, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company’s consolidated financial statements.

Milestone Payment Liability (Ta

Milestone Payment Liability (Tables)	12 Months Ended
	Jun. 30, 2024
Business Combinations [Abstract]
Schedule Of Milestone Payment Liability	The discount rate was based on published rates for corporate bonds and the term was based on an estimate of the planned timing of completion of the respective development achievement that would result in payment of the respective milestones. $ Balance – June 30, 2022 163 Change in fair value estimate 3 Balance – June 30, 2023 166 Change in fair value estimate 20 Balance – June 30, 2024 186

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	$ Balance, June 30, 2022 90 Additions 679 Less depreciation ( 60 ) Balance, June 30, 2023 709 Additions 20 Less depreciation ( 55 ) Balance, June 30, 2024 674 At June 30, 2024, the total capitalized cost of property and equipment was $ 879 (June 30, 2023 - $ 859 ), of which $ 499 is not in use. The Company has recognized $ 55 (2023 - $ 60 ) in depreciation expense for the year ended June 30, 2024, on equipment in use.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2024
Class Of Stock [Line Items]
Summary of Aggregate Information on all Equity Compensation Plans	The following table sets forth the aggregate information on all equity compensation plans as of June 30, 2024: Plan Category (in thousands, except per share amounts) Number of shares of common stock to be issued upon exercise of outstanding stock options and rights Weighted-average exercise price of stock options and rights Number of shares of common stock remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) Equity compensation plans approved by security holders - 2017 Plan (1) 288 $ 21.40 144 Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan — $ 2,060.08 — Totals 288 $ 30.70 144 (1) The Del Mar (BC) 2013 Amended and Restated Stock Option Plan refers to the Company’s previous equity compensation plan. (2) The balance of 144 shares of common stock available for issuance under the 2017 Plan as of June 30, 2024, is net of stock options previously exercised.
Schedule of Stock Option Expense	The Company has recognized the following amounts as stock option expense for the periods noted: Years ended June 30, 2024 2023 Research and development 187 451 General and administrative 420 1,039 607 1,490
Schedule of Unvested Stock Options	The following table sets forth changes in unvested stock options under all plans: Number of Weighted Unvested at June 30, 2022 84 51.23 Granted 78 8.79 Vested ( 44 ) 48.53 Unvested at June 30, 2023 118 24.12 Granted 89 4.66 Vested ( 70 ) 19.44 Forfeited ( 31 ) 8.26 Unvested at June 30, 2024 106 15.57
Schedule of Restricted Stock Units	Number of Balance – June 30, 2022 — Issuance 78 Balance – June 30, 2023 78 Vested and converted to common shares ( 4 ) Forfeited ( 8 ) Balance – June 30, 2024 66
Schedule of Warrants	The following table sets forth changes in outstanding warrants: Number of Weighted average exercise price Balance – June 30, 2022 720 49.36 Expiry of 2018 Investor and Agent warrants ( 7 ) 625.68 Balance – June 30, 2023 713 43.55 Expiry of warrants issued for services ( 20 ) 71.53 Expiry of 2019 Investor and Agent warrants ( 16 ) 157.25 Balance – June 30, 2024 677 39.99
Schedule of Changes in Outstanding Warrants	The following table summarizes the Company’s outstanding warrants as of June 30, 2024: Description of warrants Number Exercise Expiry date 2022 April Investor warrants 325 20.50 April 14, 2027 2022 Investor warrants 240 62.50 March 28, 2025 2020 Investor warrants 65 50.00 August 16, 2024 NBTS Warrants 3 54.50 June 19, 2025 2022 April Agent warrants 32 33.12 October 14, 2026 2022 Agent warrants 12 78.12 March 28, 2025 677
Series C Warrants
Class Of Stock [Line Items]
Schedule of Changes in Outstanding Warrants	The following table summarizes the Company’s outstanding Series C Agent Warrants as of June 30, 2024: Series C Agent Warrants Number Conversion Number of Cumulative Series 1 1,929 58.00 33 23 Series 2 219 60.70 4 3 Series 3 296 57.50 5 4 2,444 42 30
Schedule of Conversion of Series C Preferred Stock to Series C Warrants	The following table sets forth changes in outstanding Series C Agent Warrants: Balance, Number of Number of Balance, Exercise Issuance of Preferred Series C-1 Agent Warrants 1,929 — — 1,929 58.00 Issuance of Preferred Series C-2 Agent Warrants 219 — — 219 60.70 Issuance of Preferred Series C-3 Agent Warrants 296 — — 296 57.50 2,444 — — 2,444
Employee Stock Option
Class Of Stock [Line Items]
Schedule of Outstanding Under the Legacy Plan	The following table sets forth changes in stock options outstanding under all plans: Number of Weighted Balance – June 30, 2022 176 87.05 Granted 78 8.79 Expired ( 56 ) 102.65 Balance – June 30, 2023 198 51.71 Granted 89 4.66 Expired ( 34 ) 107.69 Forfeited ( 31 ) 8.26 Balance – June 30, 2024 222 30.70
Summary of Stock Options Currently Outstanding and Exercisable	The following table summarizes stock options outstanding and exercisable under all plans at June 30, 2024: Exercise price Number Weighted Number 4.655 79 9.17 21 6.04 9 8.64 3 8.79 34 8.09 17 12.75 to 16.25 6 8.27 6 30.50 to 48.00 73 7.31 48 62.00 to 68.50 13 6.81 13 85 7 6.21 7 304.95 to 2,660.00 1 1.93 1 222 116
Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model	Stock options issued during the years ended June 30, 2024, and 2023, have been valued using a Black-Scholes pricing model with the following assumptions: June 30, June 30, Dividend rate — % — % Volatility 91.4 % 91.4 % Risk-free rate 4.24 % 2.67 % Term – years 6.1 6.1
Performance stock units [Member]
Class Of Stock [Line Items]
Schedule of Issuance of Series C Preferred Stock	Series C Preferred Stock Number $ Balance – June 30, 2022 16,838 12,275 Conversion of Series C Preferred stock to common stock ( 2,630 ) ( 1,909 ) Balance – June 30, 2023 14,208 10,366 Conversion of Series C Preferred stock to common stock ( 540 ) ( 393 ) Balance – June 30, 2024 13,668 9,973
Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Future Dividends	The Company’s Series C Preferred Stock outstanding, conversion shares, and future dividends as of June 30, 2024, are as follows: Series Number Conversion Price Number of conversion shares Dividend Shares Series 1 10,925 58.00 188 151 Series 2 898 60.70 15 10 Series 3 1,845 57.50 32 24 13,668 235 185 Series C Dividends Dividend Shares 10% - August 19, 2021 (actual) 34 15% - August 19, 2022 (actual) 43 20% - August 19, 2023 (actual) 49 25% - August 19, 2024 (actual) 59 185

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Reconciliation Of Tax Computed At The Statutory Rates To The Income Tax Provision Recognized	Significant components of the Company’s deferred tax assets and deferred tax liabilities are shown below: June 30, June 30, Deferred tax assets: Non-capital losses carried forward 27,911 29,204 Stock-based compensation 1,149 982 Capital losses carried forward — 18 Financing costs — 326 Bonus - compensation 375 37 Scientific research and development 806 895 Scientific research and development – Investment 685 769 Capitalized research and development expenses 604 265 31,530 32,496 Deferred tax liabilities: Scientific research and development – ITC ( 114 ) ( 127 ) Fixed Assets ( 71 ) — 31,345 32,369 Valuation allowance ( 31,345 ) ( 32,369 ) Net future tax assets — —
Schedule of Components Of The Provision For Income Taxes	The differences arise from the following items: June 30, June 30, Tax recovery at statutory income tax rates ( 1,747 ) ( 3,076 ) Permanent differences 389 ( 1,095 ) Rate change ( 17 ) — Effect of rate differentials between jurisdictions ( 110 ) ( 127 ) Effect of foreign exchange rates 441 66 Scientific research and development – ITC — ( 61 ) Adjustment to prior year's provision versus statutory tax returns 2,075 ( 106 ) Other ( 7 ) 13 Change in valuation allowance ( 1,024 ) 4,386 Current income tax expense — —

Supplementary Statement of Ca_2

Supplementary Statement of Cash Flows Information (Tables)	12 Months Ended
	Jun. 30, 2024
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplementary Statement of Cash Flows Information	Year ended Year ended Series C Preferred Stock common stock dividend (note 8) 173 362 Series A Preferred Stock cash dividend in accounts payable 2 — Non-cash issue costs (note 8) — 289 Equipment additions reclassified from prepaid expenses — 447 Conversion of Series C Preferred Stock to common stock (note 8) 393 — Income taxes paid — — Interest paid — —

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Jun. 30, 2024
Risks and Uncertainties [Abstract]
Schedule of Balances in Foreign Currencies	Balances in foreign currencies at June 30, 2024, and 2023, were as follows: June 30, June 30, Trade payables 63 51 Cash 5 13 Interest, taxes, and other receivables 9 8
Schedule of Fair Value of Off-Balance Sheet Risks	Cash and Insured Non- 4,909 527 4,382

Nature of Operations, Corpora_2

Nature of Operations, Corporate History, and Going Concern and Management Plans - Additional Information (Detail) $ / shares in Units, $ in Thousands				9 Months Ended	12 Months Ended
	Apr. 02, 2024 USD ($) Patients $ / shares	Jun. 28, 2023 USD ($)	Aug. 02, 2022 USD ($) shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares
Net Income (Loss)					$ (8,320)	$ (14,649)
Negative cash flow from operations					(7,176)	(11,865)
Cash and cash equivalents				$ 4,909	4,909	1,535
Accumulated deficit				$ (159,876)	$ (159,876)	$ (151,375)
Stock issued during period shares new issues | shares			662,000
Net proceeds available under the stock purchase agreement			$ 2,008
Proceeds from grant funding		$ 2,000
Description of grant funding received					In addition, on June 28, 2023, the Company announced that it had been awarded approximately $2,000 in grant funding to be received over a two-year period for its REM-001 project.
Substantial Doubt about Companys Ability to Continue Going Concern Period					1 year
Common stock, par value | $ / shares				$ 0.001	$ 0.001	$ 0.001
Minimum of number of patients enrolled | Patients	10
Termination fees payable	$ 1,000
Tu H U R A Biosciences, Inc. [Member]
Description of contingent value rights					Existing Company stockholders will receive contingent value rights (“CVR”), entitling them to receive shares of the Company's common stock upon achievement of enrollment of a minimum of 10 patients in the REM-001 clinical trial, with such patients each completing 8 weeks of follow-up on or before December 31, 2025.
Tuhura [Member]
Common stock, par value | $ / shares	$ 0.001
Termination fees payable	$ 1,000
Tuhura [Member] | Contingent Value Rights [Member] | Maximum [Member]
Equity method investment, ownership percentage	94.55%
Tuhura [Member] | Contingent Value Rights [Member] | Minimum [Member]
Equity method investment, ownership percentage	97.15%
Merger Agreement [Member]
Reimbursement of expenses	$ 750
Merger Agreement [Member] | Contingent Value Rights [Member] | Maximum [Member]
Equity method investment, ownership percentage	5.45%
Merger Agreement [Member] | Contingent Value Rights [Member] | Minimum [Member]
Equity method investment, ownership percentage	2.85%
Merger Agreement [Member] | Tuhura [Member]
Reimbursement of expenses	$ 750
Lincoln Park Purchase Agreement [Member]
Number of shares issued in transaction | shares					400,000
Sale of stock, consideration received on transaction					$ 105
At The Market Facility [Member]
Number of shares issued in transaction | shares				53,151,000	53,151,000
Sale of stock, consideration received on transaction				$ 10,471	$ 10,471

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Detail)		12 Months Ended
	Nov. 10, 2022 shares	Jun. 30, 2024 USD ($) Segment shares	Jun. 30, 2023 shares	Jun. 30, 2021 Segment
Significant Accounting Policies (Textual)
Reverse stock split	50
Reverse stock split, description		As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock.
Reverse stock split, shares	50
Additional uncertain tax provisions | $		$ 0
Number of operating segments | Segment		1		1
Number of reportable segments | Segment		1
Minimum [Member]
Significant Accounting Policies (Textual)
Property and equipment useful life		3 years
Maximum [Member]
Significant Accounting Policies (Textual)
Property and equipment useful life		7 years
Restricted Stock Units [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		66,000	78,000
Series C Preferred Share Warrants [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		42,000	42,000
Series C Convertible Preferred Shares [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		235,000	245,000
Employee Stock Option
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		222,000	198,000
Warrant [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding		677,000	713,000

Milestone Payment Liability - A

Milestone Payment Liability - Additional Information (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2024 USD ($)
Phase 2B Clinical Study [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Cash or equivalent to common stock	$ 300
Contingent amounts payable to St. Cloud	240
Cash paid to employees	60
REM-001 Therapy [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Cash or equivalent to common stock	700
Contingent amounts payable to St. Cloud	560
Cash paid to employees	$ 140

Milestone Payment Liability - S

Milestone Payment Liability - Schedule of Milestone Payment Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Business Combinations [Abstract]
Balance	$ 166	$ 163
Change in fair value estimate	20	3
Balance	$ 186	$ 166

Clinical Trial Deposit - Additi

Clinical Trial Deposit - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Other Liabilities [Abstract]
Patient enrollment milestones, payments (recovery)	$ 563	$ 5,065
Deposits payments	1,075
Clinical trial deposit payments	205
Contract Research Organization Termination Cost	$ 1,000

Clinical Trials Grant - Additio

Clinical Trials Grant - Additional Information (Detail) $ in Thousands		12 Months Ended
	Jul. 01, 2023 USD ($) Tranches	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 2,000
Number of Tranches | Tranches	2
Research and Development [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants		$ 827	$ 0
Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 1,250
Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from award grants	$ 750

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property Equipment and Intangibles, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property Plant And Equipment [Line Items]
Beginning Balance	$ 709	$ 90
Additions	20	679
Less depreciation and amortization	(55)	(60)
Ending Balance	$ 674	$ 709

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Capitalized cost of property and equipment	$ 879	$ 859
Capitalized cost of property and equipment not in use	499
Depreciation expense	$ 55	$ 60

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2024	Jun. 30, 2023	Feb. 13, 2024
Preferred stock, par value		$ 0.001	$ 0.001
Dividends payable		$ 6	$ 8
Related party payables		52	298
Valent Assignment Agreement [Member]
Percentage of net sales				5%
Related Party
Related party payables		$ 52	$ 298
Preferred Stock Series A
Preferred Stock, shares issued		279,000	279,000
Preferred stock, rate of dividend	3%
Valent Technologies LLC [Member]
Loan payable outstanding amount	$ 279
Aggregate accrued interest	$ 29
Dividends payable		$ 8	$ 8
Valent Technologies LLC [Member] | Preferred Stock Series A
Preferred Stock, shares issued	279
Preferred stock, par value	$ 1

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Issuance of Series C Preferred Stock (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Class Of Stock [Line Items]
Conversion of Series C Preferred stock to common stock	$ 393
Series C Preferred Stock
Class Of Stock [Line Items]
Beginning Balance	$ 10,366	$ 12,275
Beginning Balance, shares	14,208	16,838
Conversion of Series C Preferred stock to common stock	$ (393)	$ (1,909)
Conversion of series C preferred stock to common stock, shares	(540)	(2,630)
Ending Balance	$ 9,973	$ 10,366
Ending Balance, shares	13,668	14,208

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands					1 Months Ended		12 Months Ended
	Aug. 19, 2024	Aug. 19, 2023	Aug. 19, 2022	Aug. 19, 2021	Aug. 31, 2020	Sep. 30, 2014	Jun. 30, 2024	Jun. 30, 2023
Class Of Stock [Line Items]
Preferred stock, par value							$ 0.001	$ 0.001
Series C Preferred Stock
Class Of Stock [Line Items]
Dividends, Preferred Stock		$ 49,000
Sale of stock price per share		$ 3.53
Preferred stock		$ 173,000					$ 9,973,000	$ 10,366,000
Liquidation value							$ 9,973,000	$ 10,366,000
Preferred Stock, shares issued							14	14
Series C Preferred Stock | Subsequent Event [Member]
Class Of Stock [Line Items]
Dividend rate	25%
Preferred stock, rate of dividend	25%
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price							$ 58
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Conversion price							60.7
Series C-3 Preferred Shares
Class Of Stock [Line Items]
Conversion price							$ 57.5
Preferred Stock Series A
Class Of Stock [Line Items]
Preferred stock							$ 279,000	$ 279,000
Liquidation value							$ 279,000	$ 279,000
Preferred Stock, shares issued							279	279
Preferred stock, rate of dividend						3%
Change in preferred stock							$ 0	$ 0
Preferred Stock Series A | Exchange Agreement
Class Of Stock [Line Items]
Preferred Stock, shares issued						279
Preferred stock, par value						$ 1
Preferred stock, rate of dividend						3%
Merger Agreement [Member] | Series C Preferred Stock | First Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate				10%
Merger Agreement [Member] | Series C Preferred Stock | Second Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate			15%
Merger Agreement [Member] | Series C Preferred Stock | Third Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate		20%
Merger Agreement [Member] | Series C Preferred Stock | Fourth Anniversary [Member] | Subsequent Event [Member]
Class Of Stock [Line Items]
Dividend rate	25%
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock
Class Of Stock [Line Items]
Shares issued of common stock for services					25,028
Shares issued, price per share					$ 1,000
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock | First Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate							10%
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock | Second Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate							15%
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock | Third Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate							20%
Merger Agreement [Member] | Private Placement [Member] | Series C Preferred Stock | Fourth Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate							25%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands							9 Months Ended	12 Months Ended
	Jul. 01, 2024	Dec. 18, 2023	Sep. 19, 2023	Jun. 01, 2023	Aug. 02, 2022	Aug. 01, 2022	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 29, 2023
Class Of Stock [Line Items]
Stock issued during period shares new issues					662,000
Common stock shares authorized							75,000,000	75,000,000	75,000,000
Sales agreement aggregate offering price		$ 10,900
Payment of prior year issuance costs									$ 43
Net proceeds available under the stock purchase agreement					$ 2,008
Common stock, shares issued							55,305,000	55,305,000	1,692,000
Shares issued for services, shares									16,000
Shares issued for services									$ 110
Number of options granted								89,000	78,000
Weighted average contractual term								7 years 8 months 19 days	8 years 9 months 29 days
Purchase Agreement [Member]
Class Of Stock [Line Items]
Sale of stock price per share					$ 10.12
Stock issued during period shares new issues					33,000
Net proceeds available under the stock purchase agreement									$ 1,903
Common stock, shares issued									229,000
Maximum committed purchase obligation					$ 2,000
Aggregate number of shares sell					262,000
Percentage of aggregate number of shares sell					19.99%
Maximum [Member] | Purchase Agreement [Member]
Class Of Stock [Line Items]
Amount of purchase common stock issued					$ 20,000
2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Common stock, shares issued							440,000	440,000
Percentage of fully diluted shares of common stock								8%
2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Stock option vesting description								vest as to 25% on August 30, 2024, with the remaining portion vesting in equal monthly installments over a period of 36 months from September 30, 2024 to September 30, 2027. All of the options to purchase shares of common stock granted have a 10-year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions.
Stock option term								10 years
Employee Stock Option
Class Of Stock [Line Items]
Number of options granted								89,000	78,000
Stock option exercise price							$ 4.655	$ 4.655
Vesting rights, percentage								25%
Aggregate intrinsic value of stock options outstanding							$ 0	$ 0	$ 0
Aggregate intrinsic value of stock options exercisable							0	0	0
Unrecognized compensation expense							322	$ 322
Unrecognized compensation expense, term								2 years 7 days
Aggregate intrinsic value of unvested stock options								$ 0	$ 0
Restricted Stock Units [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues								4,000
Number of options granted									78,000
Total expense for restricted stock units issuance				$ 186		$ 155
Vesting period				1 year		4 years
Vested and converted to common shares								4,000
Amount recognized related to RSU							$ 171	$ 171	$ 90
Restricted Stock Units [Member] | Subsequent Event [Member]
Class Of Stock [Line Items]
Vested and converted to common shares	60,000
Regular Purchase [Member] | Purchase Agreement [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues					10,000
Common stock
Class Of Stock [Line Items]
Common stock shares authorized									75,000,000	5,500,000
Officers [Member] | Restricted Stock Units [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues				60,000		18,000
Stock option commencing date, Description				Subject to providing continuous service to the Company, the RSUs all fully vest on June 1, 2024.		Subject to providing continuous service to the Company, the RSUs vest in four equal annual installments commencing August 1, 2023
Private Placement [Member] | Series C Preferred Stock Warrants [Member]
Class Of Stock [Line Items]
Shares issued of common stock for services								2,504,000
Shares issued, price per share							$ 1,000	$ 1,000
ATM Facility [Member]
Class Of Stock [Line Items]
Sale of stock price per share							$ 0.21	$ 0.21
Sales agreement aggregate offering price			$ 2,850
Net proceeds							$ 10,471	$ 10,471
Payment of prior year issuance costs							$ 435
Aggregate number of shares sell							53,151,000	53,151,000
ATM Facility [Member] | Sales Agreement [Member]
Class Of Stock [Line Items]
Commission rate			3%
Lincoln Park [Member]
Class Of Stock [Line Items]
Sale of stock price per share							$ 0.23	$ 0.23
Net proceeds								$ 105
Aggregate number of shares sell								400,000

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Future Dividends (Detail) shares in Thousands	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	10,925
Conversion price | $ / shares	$ 58
Number of conversion shares	188
Dividend Shares (in thousands)	151
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	898
Conversion price | $ / shares	$ 60.7
Number of conversion shares	15
Dividend Shares (in thousands)	10
Series C-3 Preferred Shares
Class Of Stock [Line Items]
Number	1,845
Conversion price | $ / shares	$ 57.5
Number of conversion shares	32
Dividend Shares (in thousands)	24
Series C Preferred Stock
Class Of Stock [Line Items]
Number	13,668
Number of conversion shares	235
Dividend Shares (in thousands)	185
Series C Preferred Stock | 10% - August 19, 2021 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	34
Series C Preferred Stock | 15% - August 19, 2022 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	43
Series C Preferred Stock | 20% - August 19, 2023 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	49
Series C Preferred Stock | 25% - August 19, 2024 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	59

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Aggregate Information on all Equity Compensation Plans (Details) shares in Thousands	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock to be issued upon exercise of outstanding stock options and rights	288
Weighted-average exercise price of stock options and rights | $ / shares	$ 30.7
Number of shares of common stock remaining available for future issuance under equity compensation plans	144
Equity Compensation Plans Approved by Security Holders - 2017 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock to be issued upon exercise of outstanding stock options and rights	288
Weighted-average exercise price of stock options and rights | $ / shares	$ 21.4
Number of shares of common stock remaining available for future issuance under equity compensation plans	144
Equity Compensation Plans Not Approved by Security Holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average exercise price of stock options and rights | $ / shares	$ 2,060.08

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Aggregate Information on all Equity Compensation Plans (Parenthetical) (Detail) shares in Thousands	Jun. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock remaining available for future issuance under equity compensation plans	144
Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares of common stock remaining available for future issuance under equity compensation plans	144

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Outstanding Under the Legacy Plan (Detail) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	89,000	78,000
Ending balance	222,000
Exercised	$ 30.7
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	198,000	176,000
Granted	89,000	78,000
Expired	(34,000)	(56,000)
Forfeited	(31,000)
Ending balance	222,000	198,000
Beginning balance	$ 51.71	$ 87.05
Granted	4.66	8.79
Expired	107.69	102.65
Forfeited	8.26
Ending balance	$ 30.70	$ 51.71

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Stock Options Outstanding and Exercisable (Detail)	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	222,000
Stock options exercisable	116,000
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 4.655
Number of stock options outstanding	79,000
Weighted average remaining contractual life (years)	9 years 2 months 1 day
Stock options exercisable	21,000
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 6.04
Number of stock options outstanding	9,000
Weighted average remaining contractual life (years)	8 years 7 months 20 days
Stock options exercisable	3,000
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 8.79
Number of stock options outstanding	34,000
Weighted average remaining contractual life (years)	8 years 1 month 2 days
Stock options exercisable	17,000
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	6,000
Weighted average remaining contractual life (years)	8 years 3 months 7 days
Stock options exercisable	6,000
Exercise Price Four [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 12.75
Exercise Price Four [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 16.25
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	73,000
Weighted average remaining contractual life (years)	7 years 3 months 21 days
Stock options exercisable	48,000
Exercise Price Five [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 30.5
Exercise Price Five [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 48
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	13,000
Weighted average remaining contractual life (years)	6 years 9 months 21 days
Stock options exercisable	13,000
Exercise Price Six [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 62
Exercise Price Six [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	68.5
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 85
Number of stock options outstanding	7,000
Weighted average remaining contractual life (years)	6 years 2 months 15 days
Stock options exercisable	7,000
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding	1,000
Weighted average remaining contractual life (years)	1 year 11 months 4 days
Stock options exercisable	1,000
Exercise Price Eight [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 304.95
Exercise Price Eight [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 2,660

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model (Detail) - Stock options [Member]	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Class of Stock [Line Items]
Volatility rate	91.40%	91.40%
Risk-free interest rate	4.24%	2.67%
Expected term	6 years 1 month 6 days	6 years 1 month 6 days

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Stock Option Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 607	$ 1,490
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	187	451
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 420	$ 1,039

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Unvested Stock Options (Detail) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Equity [Abstract]
Beginning balance	118,000	84,000
Granted	89,000	78,000
Vested	(70,000)	(44,000)
Forfeited	(31,000)
Ending balance	106,000	118,000
Beginning balance	$ 24.12	$ 51.23
Granted	4.66	8.79
Vested	19.44	48.53
Forfeited	8.26
Ending balance	$ 15.57	$ 24.12

Stockholders' Equity - Schedu_7

Stockholders' Equity - Schedule of Restricted Stock Units (Details) - shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance	118,000	84,000
Issuance	89,000	78,000
Vested and converted to common shares	(70,000)	(44,000)
Forfeited	(31,000)
Ending balance	106,000	118,000
Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance	78,000	0
Issuance		78,000
Vested and converted to common shares	(4,000)
Forfeited	(8,000)
Ending balance	66,000	78,000

Stockholders' Equity - Schedu_8

Stockholders' Equity - Schedule of Warrants (Detail) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Weighted-average exercise price of stock options and rights	$ 30.7
Warrant [Member]
Beginning Balance	713,000	720,000
Beginning balance	$ 43.55	$ 49.36
Ending balance	677,000	713,000
Ending balance	$ 39.99	$ 43.55
Warrant [Member] | 2018 Investor and Agent Warrants [Member]
Expiry of warrants		(7,000)
Expired		$ 625.68
Warrant [Member] | 2019 Investor and Agent Warrants [Member]
Expiry of warrants	(16,000)
Expired	$ 157.25
Common Stock Warrants [Member] | Issued For Services One [Member]
Expiry of warrants	(20,000)
Expired	$ 71.53

Stockholders' Equity - Schedu_9

Stockholders' Equity - Schedule of Outstanding Warrants (Detail) - Warrant [Member]	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Number	677,000
Investor One [Member]
Number	325,000
Warrants exercise price | $ / shares	$ 20.50
Expiry date	Apr. 14, 2027
Investor Two [Member]
Number	240,000
Warrants exercise price | $ / shares	$ 62.5
Expiry date	Mar. 28, 2025
Investor Three [Member]
Number	65,000
Warrants exercise price | $ / shares	$ 50
Expiry date	Aug. 16, 2024
NBTS [Member]
Number	3,000
Warrants exercise price | $ / shares	$ 54.50
Expiry date	Jun. 19, 2025
Agent [Member]
Number	32,000
Warrants exercise price | $ / shares	$ 33.12
Expiry date	Oct. 14, 2026
Agent One [Member]
Number	12,000
Warrants exercise price | $ / shares	$ 78.12
Expiry date	Mar. 28, 2025

Stockholders' Equity - Sched_10

Stockholders' Equity - Schedule of Outstanding Series C Preferred Stock Warrants (Detail) - Series C Warrants	12 Months Ended
	Jun. 30, 2024 Warrant $ / shares shares
Balance	2,444,000
Number of Warrants Issued | Warrant	0
Number of Warrants Exercised	0
Balance	2,444,000
Issuance of Preferred Series C-1 Agent Warrants [Member]
Balance	1,929,000
Number of Warrants Issued | Warrant	0
Number of Warrants Exercised	0
Balance	1,929,000
Warrants exercise price | $ / shares	$ 58
Issuance of Preferred Series C-2 Agent Warrants [Member]
Balance	219,000
Number of Warrants Issued | Warrant	0
Number of Warrants Exercised	0
Balance	219,000
Warrants exercise price | $ / shares	$ 60.70
Issuance of Preferred Series C-3 Agent Warrants [Member]
Balance	296,000
Number of Warrants Issued | Warrant	0
Number of Warrants Exercised	0
Balance	296,000
Warrants exercise price | $ / shares	$ 57.50

Stockholders' Equity - Sched_11

Stockholders' Equity - Schedule of Outstanding Series C Agent Warrants (Detail) - Series C Warrants - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Number	2,444,000	2,444,000
Number of conversion shares	42,000
Cumulative common stock dividends	30,000
Series 1 Warrants Outstanding
Number	1,929,000
Warrants exercise price	$ 58
Number of conversion shares	33,000
Cumulative common stock dividends	23,000
Series 2 Warrants Outstanding Member
Number	219,000
Warrants exercise price	$ 60.70
Number of conversion shares	4,000
Cumulative common stock dividends	3,000
Series 3 Warrants Outstanding
Number	296,000
Warrants exercise price	$ 57.50
Number of conversion shares	5,000
Cumulative common stock dividends	4,000

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation Of Tax Computed At The Statutory Rates To The Income Tax Provision Recognized (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Deferred tax assets:
Non-capital losses carried forward	$ 27,911	$ 29,204
Stock-based compensation	1,149	982
Capital losses carried forward		18
Financing costs		326
Bonus - compensation	375	37
Scientific research and development	806	895
Scientific research and development – Investment Tax Credits (“ITC”)	685	769
Capitalized research and development expenses	604	265
Deferred tax assets	31,530	32,496
Deferred tax liabilities:
Scientific research and development – ITC	(114)	(127)
Fixed Assets	(71)
Gross future tax assets	31,345	32,369
Valuation allowance	$ (31,345)	$ (32,369)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2021
Current and Future Income Taxes (Textual)
Statutory income tax rate	21%	21%
Deferred tax assets, Operating loss carryforwards, Not subject to expiration	$ 33,600,000
Percentage of taxable income, limitation on NOLs	80%
Investment tax credits expire, description	expire between 2031 and 2042
Current income tax expense	$ 0
Open tax years	2020 2021 2022 2023		2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax	50%
Cumulative change in ownership period	3 years
United States [Member]
Current and Future Income Taxes (Textual)
Loss before income taxes	$ 6,500,000
Operating loss carryforwards	$ 15,800,000
Operating loss carryforwards expiration date	Jun. 30, 2028
Net operating loss expire, description	begin expiring on June 30, 2028
US and Canadian [Member]
Current and Future Income Taxes (Textual)
Operating loss carryforwards	$ 109,300,000	$ 109,300,000
Canadian [Member]
Current and Future Income Taxes (Textual)
Loss before income taxes	1,800,000
Operating loss carryforwards	$ 59,900,000
Net operating loss expire, description	begin expiring in 2030
Non-refundable federal investment tax credits	$ 421,000	470,000
British Columbia [Member]
Current and Future Income Taxes (Textual)
Investment tax credits expire, description	expire between 2024 and 2032
Non-refundable federal investment tax credits	$ 264,000	299,000
Canadian Scientific Research and Development [Member]
Current and Future Income Taxes (Textual)
Non-refundable federal investment tax credits	$ 3,100,000	$ 3,300,000

Income Taxes - Schedule of Carr

Income Taxes - Schedule of Carrying Amount Of Assets And Liabilities For Financial Reporting (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Effective income tax rate differs from the statutory income tax rate
Tax recovery at statutory income tax rates	$ (1,747)	$ (3,076)
Permanent differences	389	(1,095)
Rate change	(17)
Effect of rate differentials between jurisdictions	(110)	(127)
Effect of foreign exchange rates	441	66
Scientific research and development – ITC		(61)
Adjustment to prior year's provision versus statutory tax returns	2,075	(106)
Other	(7)	13
Change in valuation allowance	$ (1,024)	$ 4,386

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Commitments and Contingencies (Textual)
Remaining commitments related to drug manufacturing, clinical study management and safety	$ 1,852,000
Deposits related to study initiation	205,000
Rent expense	$ 14,000	$ 39,000
Head Office [Member]
Commitments and Contingencies (Textual)
Lease rent for office space term	1 year
Lease rent for office space	$ 2,400
Administrative Offices [Member]
Commitments and Contingencies (Textual)
Lease rent for office space	1,900
CAD [Member] | Administrative Offices [Member]
Commitments and Contingencies (Textual)
Lease rent for office space	$ 2,500

Supplementary Statement of Ca_3

Supplementary Statement of Cash Flows Information - Schedule of Supplementary Statement of Cash Flows Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Supplemental Cash Flow Information [Abstract]
Preferred Stock common stock dividend (note 6)	$ 173	$ 362
Series A Preferred Stock cash dividend in accounts payable	8	8
Non-cash issue costs (note 6)		289
Equipment additions reclassified from prepaid expenses		447
Conversion of Series C Preferred Stock to common stock (note 6)	393
Preferred Stock Series C
Supplemental Cash Flow Information [Abstract]
Preferred Stock common stock dividend (note 6)	173	362
Conversion of Series C Preferred Stock to common stock (note 6)	(393)	$ (1,909)
Preferred Stock Series A
Supplemental Cash Flow Information [Abstract]
Series A Preferred Stock cash dividend in accounts payable	$ 2

Financial Risk Management - Add

Financial Risk Management - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Foreign Currency Fair Value Hedge Derivative [Line Items]
Cash and cash equivalents	$ 4,909	$ 1,535
Credit risk, financial instrument maximum exposure	65
Credit risk, uninsured cash and cash equivalents	4,382
Liquidity Risk [Member]
Foreign Currency Fair Value Hedge Derivative [Line Items]
Liquidity risk maximum exposure	2,283
Foreign exchange risk [Member]
Foreign Currency Fair Value Hedge Derivative [Line Items]
Financial risk, accounts payable and accrued liabilities, net	$ 36
Maximum exposure of financial currency due to exchange rates, description	Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. If foreign exchange rates were to fluctuate within +/-10% of the closing rate at year-end, the maximum exposure is $4.
Foreign exchange risk maximum exposure	$ 4
Cash and cash equivalents	$ 4,909
Maximum exposure of interest rate risk, description	The Company’s cash balance currently earns interest at standard bank rates. If interest rates were to fluctuate within +/-10% of the closing rate at year end the impact of the Company’s interest-bearing accounts will not be significant due to the current low market interest rates.

Financial Risk Management - Sch

Financial Risk Management - Schedule of Balances in Foreign Currencies (Detail) - Foreign exchange risk [Member] - CAD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Foreign Currency Fair Value Hedge Derivative [Line Items]
Trade payables	$ 63	$ 51
Cash	5	13
Interest, taxes, and other receivables	$ 9	$ 8

Financial Risk Management - S_2

Financial Risk Management - Schedule of Fair Value of Off-Balance Sheet Risks (Detail) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Risks and Uncertainties [Abstract]
Cash and cash equivalents	$ 4,909	$ 1,535
Insured amount $	527
Non- insured amount $	$ 4,382

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - shares	Aug. 19, 2024	Jun. 30, 2024	Jun. 30, 2023
Subsequent Event [Line Items]
Common stock, shares issued		55,305,000	1,692,000
Subsequent Event [Member] | Preferred Stock Series C
Subsequent Event [Line Items]
Dividend rate	25%
Preferred stock, rate of dividend	25%
Common stock, shares issued	59,000
Subsequent Event [Member] | Series C Agent Warrants [Member] | Preferred Stock Series C
Subsequent Event [Line Items]
Preferred stock, rate of dividend	25%
Common stock, shares issued	235,000